Eli Lilly announced in a regulatory filing last week that the Department of Justice has closed its Foreign Corrupt Practices Act investigation, without bringing any charges.
As Compliance Week previously reported, the drug company reached a $29.4 million civil settlement with the Securities and Exchange Commission in 2012 for FCPA violations. It further agreed to have an independent compliance consultant conduct a 60-day review of the company’s internal controls and compliance program related to the FCPA.
